OmicsFi’s Post

🌟 Revolutionizing Cancer Treatment with Personalized Precision Medicine! 🌟 The era of personalized precision medicine is flourishing, thanks to the widespread availability of Next-Generation Sequencing (NGS) data on solid tumors. This advancement enables the rapid identification of actionable genetic alterations, leading to highly targeted treatments. * With over 40% of biomarkers proving to be functionally relevant across multiple cancers, the future of cancer chemoprevention looks incredibly promising. Exciting times ahead for oncology and patient care! #PrecisionMedicine #CancerResearch #NGS #Oncology #TargetedTherapy #FutureOfMedicine [Dreikhausen L, Klupsch A, Wiest I, Xiao Q, Schulte N, Betge J, Boch T, Brochhausen C, Gaiser T, Hofheinz RD, Ebert M, Zhan T. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study. BMC Cancer. 2024 Apr 25;24(1):526. doi: 10.1186/s12885-024-12261-2. PMID: 38664720; PMCID: PMC11046933].

The 100,000 Genomes Cancer Programme recently made a significant advancement in the field of oncology by publishing integrated whole genome sequencing (WGS) data from 13,880 solid tumors. This analysis, encompassing a vast array of tumor types, was coupled with real-world insights into treatment and outcomes. The findings underscore the potential of WGS to detect a range of genetic alterations, including somatic small variants, copy number aberrations, and structural variants, which are crucial for guiding treatment decisions. This work revealed that >90% of brain tumors and >50% of colon and lung cancers exhibited genetic changes that could influence treatment strategies. Learn more about this cutting-edge research: https://hubs.ly/Q02xj6yg0 #CancerResearch #PrecisionMedicine #Genomics

Understanding genetic factors in hereditary cancer helps tailor proactive management and preventive measures, aiming for the best possible patient outcomes and support. Some cancers have a stronger genetic predisposition, with hereditary syndromes making up around 3-20% of all cancer cases. Unilabs provides oncogenetic consultations which can unlock possible risk-reducing interventions and provide informed clinical decisions for the patient. Developments in next-generation sequencing allow us to quickly analyse multiple genes at once, helping identify harmful gene changes linked to hereditary cancers. Additionally, new treatments like PARP inhibitors and checkpoint inhibitors show promise for cancers with specific genetic mutations.  Learn more from Unilabs' Oncogenetics specialist Dr Zuzana Mazerikova.  https://lnkd.in/eN_vp_64 #Genetics #Oncology #Cancer #Healthcare 

https://lnkd.in/gWs8UBe3     Article title: Distinct genetic variants of early and late-onset prostate cancer   Author(S): Victor Chalfant#, Samuel Serrano#, Mohamed Al-Toubat*, Carlos Riveros#, Ahmed Elshafei and KC Balaji   Journal: Insights of Epigenetics and Chromatin Abstract: Background: The incidence of early-onset Prostate Cancer (PCa) has increased in the last two decades. Men diagnosed with PCa before age 55 have lower 5-year relative survival rates compared to patients diagnosed later in life. Given the enhanced lethality of early-onset PCa, our aim is to evaluate somatic differences between early and late-onset PCa. Methods: Patients with PCa were dichotomized into early (< 55 years old) and late-onset PCa (≥ 55 years old). Data is derived from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry. The GENIE registry contains sequenced tumor samples and clinical data across many cancers a total of 4,546 Patients and 5,740 samples were included with pathologically confirmed prostate adenocarcinoma. The data is derived from 17 cancer centers from 2011 to 2021. Patterns in somatic gene tumor profiles were compared between early-onset and late-onset PCa using a chi-square test and logistic regression. #Earlyonsetprostatecancer #Genesequencing #ERF #CDK12 #Genetherapeutics   #DNAMethylation #HistoneModifications #ChromatinRemodeling #EpigeneticRegulation #EpigeneticInheritance #ChromatinStructure #HistoneAcetylation #GeneExpression #EpigeneticModification #ChromatinArchitecture #ChromatinDynamics #EpigeneticMarkers #NonCodingRNAs #ChromatinOrganization #ChromatinFunction #DNAAccessibility #EpigeneticMemory #TranscriptionalRegulation #EpigeneticTherapy #ChromatinInteractions

🔬 Gene of the Month: #KRASSStory 🚀 A single mutation can change everything! 🧬 #KRAS, one of the most studied oncogenes, plays a crucial role in cell signaling. But when a mutation occurs, it can trigger a cascade of uncontrolled cell growth, leading to cancers such as:- 🔹 Lung Cancer 🔹 Pancreatic Cancer 🔹 Colorectal Cancer - disrupting normal blood cell function. 👉 One mistake, a catastrophic event! 🚨 Understanding #KRAS mutations is key to unlocking precision treatments and targeted therapies for cancer patients. With advancements in comprehensive genomic profiling, we can identify these mutations and pave the way for personalized treatment strategies. At 4baseCare we are committed to driving #innovation in precision oncology to improve patient outcomes. Let’s decode cancer, one gene at a time! #Genomics #PrecisionOncology #CancerResearch #4baseCare #KRAS #TargetedTherapies #KRAS #KRASMutations #Oncology #CancerGenetics #MolecularOncology #LungCancer #PancreaticCancer #ColorectalCancer #CancerAwareness #GeneticTesting #PersonalizedMedicine #NextGenSequencing #TumorBiology #Biomarkers

🔬 Did you know that prostate cancer is the second most common type of cancer in men with 1 out of 9 men developing it at one point in their lives? 🔎 A recent genetic research have identified mutations which may help doctors determine who are more likely to have aggressive forms of prostate cancer enabling development of more individualized therapy for such patients. 🧬 Researchers at the Institute of Cancer Research in London have added to the number of inherited genetic mutations that can raise the chances of an aggressive kind of prostate cancer. This discovery reiterates the significance of genetic influences on the intensity of cancer. In genes like ATM, MLH1, MSH2, NBN, and BRCA2, locating specific mutations enables clinicians to predict disease progression more effectively, and as a consequence, to individualize therapeutic strategies. 🌱 This can potentially lead to better results for patients as well as improved quality-of-life measures by means of better healthcare provision. Let's celebrate this milestone in cancer research and the potential it brings for improved patient care. 🌟 #Prevealth #CancerResearch #Genetics #ProstateCancer #MenHealth #HealthcareInnovation Read more: https://lnkd.in/gZFUyaEG

Precision medicine is transforming cancer care, ensuring patients receive targeted therapies based on their unique genetic profiles. The Molecular Oncology Patient Pathway streamlines this process, guiding patients from sequencing to treatment. Here’s how it works: 🧬 Tumor Sequencing – A detailed genetic analysis of tumor DNA to identify actionable mutations. 🩸 Blood Sequencing – A less invasive approach analyzing circulating tumor DNA for real-time insights. 🎯 Treatment Matching – Aligning patients with the most effective, personalized therapies based on sequencing results. 🤝 Centralized Review – Oncology boards collaborate to evaluate findings and optimize treatment strategies. This approach ensures that patients receive precision-driven, evidence-based treatments, maximizing outcomes and minimizing unnecessary interventions. Excited to see how molecular oncology continues to evolve! What are your thoughts on the impact of genomics in cancer care? 💡💬 #Oncology #PrecisionMedicine #CancerResearch #MolecularOncology #Genomics #HealthcareInnovation

In recognition of Sarcoma Awareness Month, did you know that inherited cancer gene mutations in TP53, RB1, NF1, APC, KIT, and PDGFR can raise the risk for certain sarcomas? In fact, one in ten people with osteosarcoma have an inherited cancer risk gene mutation. If you are a sarcoma patient, you may want to consider genetic testing. We ask that you also consider joining our CAUSAL study through which we trying to learn more about sarcoma patients. No travel to our center is needed, and everything can be done online. Participating in this study involves taking surveys, monitoring your physical activity with a free Fitbit, free genetic testing for inherited cancer, and free tumor testing. Your participation could help develop new ways to improve cancer treatment and quality of life as well as to learn more about sarcoma causes and prevention.   To learn more about participating, please visit https://lnkd.in/eXEPh7JB   #ICARE #InheritedCancer #HereditaryCancer #Cancer #Sarcoma #CancerResearch #CAUSAL #GeneticTesting #TP53 #RB1 #NF1 #APC #KIT #PDGFR #CancerGenomics #CancerRisks #CancerPrevention American Society of Clinical Oncology (ASCO) American Cancer Society National Cancer Institute (NCI) Vanderbilt Health VANDERBILT-INGRAM CANCER CENTER AT GREEN HILLS

🔍 How can simply looking at cells through the Deepcell lens guide cancer therapy decisions? In collaboration with AbbVie (data presented at #AACR2024), we demonstrated direct linking between cell morphology to gene expression and function in a lung cancer patient tissue biopsy.   🔬 We identified a rare malignant subpopulation (Cluster 0) with a drastically different gene expression profile compared to the majority of the patient's cancer cells (Cluster 2). 💡 Through sorting, we uncovered key differences in gene expression and pathways, including upregulation of STAT3 (which promotes tumor growth, survival, angiogenesis, immune evasion, and inflammation) and NF-kB signaling (fueling inflammation, tumor survival, resistance to apoptosis, and metastasis) in this rare subpopulation. 🎯 These insights suggest therapeutically targeting STAT3 and NF-kB signaling to effectively combat Cluster 0. The results underscore #REM-I’s potential to unveil hidden cellular subtypes, drive groundbreaking cancer therapies, and transform patient outcomes. Start your journey to harness the power of AI for your application by requesting a demo here: https://lnkd.in/g_nPdRR4 Link to AACR poster here: https://lnkd.in/gF9zA-T4 #PrecisionOncology #CancerResearch #Deepcell #AACR2024 #CancerTherapies #Morpholomics

🧬 Revolutionary Breakthrough in Cancer Genetics: Overcoming Drug Resistance 🎯 A groundbreaking study at UT Southwestern Medical Center, published in Cell, reveals a key genetic pathway that cancer cells exploit to drive malignancy and develop resistance to therapy. This pathway, involved in DNA repair, becomes hijacked by cancer cells to facilitate chromosomal shattering—a process known as chromothripsis. 🔍 What is Chromothripsis? Chromothripsis can cause massive rearrangements in a chromosome, leading to rapid genomic changes. This phenomenon is prevalent in 30-40% of all cancers, particularly aggressive types like sarcomas and glioblastomas. 💡 Study Insights by Dr. Peter Ly Dr. Peter Ly and his team utilized CRISPR technology to identify key genes in the Fanconi anemia pathway that prevent chromosome shattering when inactivated. This pathway typically repairs DNA, but when manipulated, it leads to chromosomal damage contributing to cancer progression. 🎯 Clinical Implications This discovery not only advances our understanding of cancer biology but also opens new avenues for developing treatments that prevent drug resistance. By targeting the Fanconi anemia pathway, therapies could potentially block the chromothripsis process, offering a new strategy to combat therapy-resistant cancers. 🔗 https://lnkd.in/eVtnUcaM #CancerResearch #Genomics #CRISPR #UTSouthwestern #CellBiology #Oncology